JMP Securities Reiterates Market Outperform on Iovance Biotherapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained an $18 price target.
June 05, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reiterated a Market Outperform rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained an $18 price target.
The reiteration of the Market Outperform rating and maintenance of the $18 price target by JMP Securities analyst Reni Benjamin indicates a positive outlook for Iovance Biotherapeutics. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100